@article {Brocklebanks89, author = {Vicky Brocklebank and David Kavanagh}, title = {Protecting the kidney from complement: atypical haemolytic uraemic syndrome}, volume = {14}, number = {Suppl 6}, pages = {s89--s94}, year = {2014}, doi = {10.7861/clinmedicine.14-6-s89}, publisher = {Royal College of Physicians}, abstract = {Atypical haemolytic uraemic syndrome is a thrombotic microangiopathy with a predominant renal phenotype. Research developments in the last 15~years have led to the elucidation of the role of complement over activation in the pathogenesis of the disease. This was to lead to the successful introduction of targeted pharmacological therapy, in the form of the complement inhibitor, eculizumab.}, issn = {1470-2118}, URL = {https://www.rcpjournals.org/content/14/Suppl_6/s89}, eprint = {https://www.rcpjournals.org/content/14/Suppl_6/s89.full.pdf}, journal = {Clinical Medicine} }